Parkinson's disease

Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

ANAVEX®2-73 Shown to have Neurorestorative Effects in a Model for Experimental Parkinsonism NEW YORK, NY – October 30, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain…